Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Discovery & Development Small Molecules, Technology and Equipment, Analytical Science

Planning for Production Scale

The design and development of the optimal production process is a big challenge – and it’s rare that upscaling runs smoothly. The growing demand of monoclonal antibodies (mAbs) requires efforts to increase production capacities and product titers. Experience shows that an ideal up-scaling process tends to rely on the field of hydrodynamics and process engineering; numerous indicators and values are needed to develop the right strategy. Many parameters, such as mixing time and the volumetric mass transfer coefficient (kLa), however, cannot be transferred in a linear manner, so successful up-scaling always involves compromises.

Enjoy our FREE content!

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login if you already created an account

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login as a Guest or via Social Media

About the Author

Daniel Maier

Daniel Maier, Director of Engineering and Services at Zeta Biopharma, Germany.

Register here

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register

December Issue of The Medicine Maker